Scandion Oncology

Overcoming cancer drug resistance

Navbar
  • About us
    • Executive Management
    • Board of Directors
    • Clinical Advisory Board
  • Research & Development
    • Pipeline
    • Clinical Development
    • Science
      • Cancer drug resistance
      • Technology Platform
      • SCO-101
  • News & Press
    • Press releases
    • Media
      • Image library
      • Video library
  • Investors
    • Share information
    • Financial calendar
    • Financial Reports
      • Annual reports
      • Interim reports
    • Presentations
    • Business development
    • Analyst Coverage
    • Prospectuses
      • Rights Issue 2022
      • Rights Issue 2020
      • Rights Issue 2019
      • Subscription Warrant (SCOL TO 1)
      • IPO 2018
    • Corporate governance
    • Events
      • General meetings
  • Contact
    • Career
Skip to content

Presentations

AllInvestor PresentationsScientific Presentations
24 April 2023

Swiss Biotech Day Basel, April 24-25, 2023

Swiss Biotech Day Basel, April 24-25, 2023
30 March 2023

Swiss Nordic Bio Zurich

Swiss Nordic Bio Zurich, March 30, 2023
28 November 2022

Redeye Life Science Day

Infocus interview with CEO Johnny Stilou at Redeye Life Science Day 2022.
26 October 2022

Økonomisk Ugebrev conference

Watch the presentation by acting CEO and CFO Johnny Stilou.
24 October 2022

BIO-Europe 2022

See the slide deck.
13 October 2022

Investor AW

Watch the presentation by VP Mads Aaboe Jensen.
10 October 2022

DAF visit to Scandion

See the slide deck here.
4 October 2022

Conference call on CORIST

See the presentation or replay the conference call.
16 June 2022

Redeye Transactions

Watch President & CEO Bo Rode Hansen’s presentation from Redeye Transactions
14 June 2022

Aktiespararna

Watch Chief Operating Officer Maj Hedtjärn present Scandion at Aktiespararna Småbolagsdagarna 2022
11 June 2022

DAF Interview

Watch President and CEO Bo Rode Hansen present Scandion to The Danish Shareholder Association
10 June 2022

Investor Call

Watch the presentation from the Investor call on June 10, 2022
  1. Frontpage

About us

  • About us
  • Executive Management
  • Board of Directors
  • Clinical Advisory Board

Research & Development

  • Research & Development
  • Pipeline
  • Clinical Development
  • Science

News & Press

  • Press releases
  • Other news
  • Media
    • Image library items
    • Video library items

Investors

  • Investors
  • Share information
  • Financial Reports
  • Presentations
  • Analyst Coverage
  • Prospectuses
  • Corporate governance
  • Events

Contact us

Scandion Oncology A/S
Symbion
Fruebjergvej 3
2100 Copenhagen
Denmark

Phone: +45 38 10 20 17
info@scandiononcology.com

Media and Investor relations:
Email: ir@scandiononcology.com
Phone: +45 29 60 35 32

Follow us


Scandion Oncology - The Cancer Drug Resistance Company

Our vision is to overcome cancer drug resistance in order to improve lives for cancer patients and their families

© Copyright 2022 - Scandion Oncology A/S | We use cookies to improve our services | Disclaimer: Market data could be delayed. Delivered by Cision.